Stocks in focus in the morning session included Inobcell, following completion of the US IND review for the international Phase III ICEF15 clinical trial, and Dentsu Soken, following Dentsu Group's policy to take it private.
The US FDA conducted a 30-day review of the IND application submitted for the international Phase III ICEF15 clinical trial, and notification was received that the trial could begin in the US. This is expected to allow the formal enrollment of US sites and patients in the ICEF15 trial to proceed.
Dentsu Group was reported to have a policy to take Dentsu Soken private, with the investment amount expected to be approximately ¥200 billion. Dentsu Group is expected to maintain an ownership stake of more than 60%, and the tender offer is expected to launch in July. The unwinding of the parent-subsidiary listing structure is attracting investor attention.
The move to take Dentsu Soken private could strengthen market expectations for an acquisition premium, while it is said that there is currently little information requiring disclosure.
Developments involving stocks such as Daiseki and OSG were also reported, but the article focused mainly on Inobcell and Dentsu Soken.